Program
Anti-CD20 Bispecific Antibody DR-0201
Also written as “SAR448501” and “DR-0201”.
In Sanofi’s pipeline, CD20 bispecific mAb
. Its studies are mostly in Lupus Erythematosus, Systemic · Lymphoma, B-Cell, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 22 open or running | phase 1since Apr 23, 2024 | Apr 23, 2024 | Jan 21, 2028phase 1 · NCT06392477 |
| Dren Bio | 10 open or running | phase 1since Aug 14, 2023 | Aug 14, 2023 | none ahead |
- Named in Sanofi’s own pipeline as
SAR448501
, phase 1, as of Sep 30, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 14, 2023First study: phase 1 study in Healthy Adult VolunteersNew to Dren BioDren Bio · NCT06008652 · 10 enrolled · Australia
- Apr 23, 2024Sanofi’s first study: phase 1 study in Lymphoma, B-CellNew to SanofiSanofi · NCT06392477 · 96 planned · Australia, Serbia, Singapore and more
- Oct 16, 2024Phase 1 study in Lupus Erythematosus, SystemicSanofi · NCT06647069 · 62 planned · Australia, Bosnia and Herzegovina, Georgia and more
Ahead
- Jan 21, 2028Primary completion: phase 1 study in Lymphoma, B-CellSanofi · NCT06392477
- Jun 25, 2029Primary completion: phase 1 study in Lupus Erythematosus, SystemicSanofi · NCT06647069
TargetBeta
“CD20 bispecific mAb”the company's pipeline, read by Claude · source
“A bispecific monoclonal antibody that targets the human tumor-associated antigen (TAA) CD20, with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD20 bispecific antibody DR-0201 targets and binds to CD20 on B-cell surface. This results in CD20-mediated signali…”NCIt, read by Claude
Other programs on MS4A1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Rituximabrule | Hoffmann-La Roche | phase 4 | 175 |
| ocrelizumabrule | Hoffmann-La Roche | phase 4 | 42 |
| obinutuzumabrule | Hoffmann-La Roche | phase 4 | 42 |
| ublituximabrule | TG Therapeutics | phase 3 | 23 |
| mosunetuzumabrule | Hoffmann-La Roche | phase 3 | 14 |
| glofitamabrule | Hoffmann-La Roche | phase 3 | 13 |
| epcoritamabrule | Genmab | phase 3 | 13 |
| Anti-CD20 Monoclonal Antibody MIL62rule | beijing-mabworks-biotech-co-ltd | phase 3 | 10 |
| odronextamabrule | Regeneron Pharmaceuticals | phase 3 | 8 |
| TQB2825 | Sino Biopharmaceutical | phase 3 | 5 |
| zuberitamabrule | bioray-pharmaceutical-co-ltd | phase 3 | 3 |
| rondecabtagene autoleucelrule | lyell-immunopharma-inc | phase 3 | 2 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06647069Lupus Erythematosus, Systemic · Australia, Bosnia and Herzegovina, Georgia and more | 1 | Recruiting | Sanofi | Jun 25, 2029 | 62 |
| NCT06392477Lymphoma, B-Cell · Australia, Serbia, Singapore and more | 1 | Recruiting | Sanofi | Jan 21, 2028 | 96 |
| NCT06008652Healthy Adult Volunteers · Australia | 1 | Completed | Dren Bio | Jul 24, 2024 | 10 |
How it is read
Names in the registry
- “SAR448501”, 2 entries
- “DR-0201”, 1 entry
Conditions, from the studies’ own filings
- Lupus Erythematosus, Systemic, 1 study
- Lymphoma, B-Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.